369 related articles for article (PubMed ID: 29856649)
1. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR; Antonarakis ES; Ryan CJ; Berry WR; Shore ND; Liu G; Alumkal JJ; Higano CS; Chow Maneval E; Bandekar R; de Boer CJ; Yu MK; Rathkopf DE
Eur Urol; 2016 Dec; 70(6):963-970. PubMed ID: 27160947
[TBL] [Abstract][Full Text] [Related]
3. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
[TBL] [Abstract][Full Text] [Related]
4. The development of apalutamide for the treatment of prostate cancer.
Isaacsson Velho P; Tofani Sant' Anna P; Pereira da Silva RF; Dal Ponte Ferreira R; Venero FC
Expert Opin Drug Discov; 2021 Mar; 16(3):217-226. PubMed ID: 33003959
[TBL] [Abstract][Full Text] [Related]
5. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
[TBL] [Abstract][Full Text] [Related]
6. Apalutamide shows efficacy in prostate cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e149. PubMed ID: 29456088
[No Abstract] [Full Text] [Related]
7. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Rathkopf DE; Smith MR; Ryan CJ; Berry WR; Shore ND; Liu G; Higano CS; Alumkal JJ; Hauke R; Tutrone RF; Saleh M; Chow Maneval E; Thomas S; Ricci DS; Yu MK; de Boer CJ; Trinh A; Kheoh T; Bandekar R; Scher HI; Antonarakis ES
Ann Oncol; 2017 Sep; 28(9):2264-2271. PubMed ID: 28633425
[TBL] [Abstract][Full Text] [Related]
8. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
[TBL] [Abstract][Full Text] [Related]
9. Darolutamide (ODM-201) for the treatment of prostate cancer.
Shore ND
Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
[TBL] [Abstract][Full Text] [Related]
10. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN; Chowdhury S; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez A; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Brookman-May S; Mundle SD; McCarthy SA; Larsen JS; Sun W; Bevans KB; Zhang K; Bandyopadhyay N; Agarwal N
J Clin Oncol; 2021 Jul; 39(20):2294-2303. PubMed ID: 33914595
[TBL] [Abstract][Full Text] [Related]
11. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
Molecules; 2020 May; 25(10):. PubMed ID: 32456317
[TBL] [Abstract][Full Text] [Related]
12. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
[TBL] [Abstract][Full Text] [Related]
13. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
Werutsky G; Maluf FC; Cronemberger EH; Carrera Souza V; Dos Santos Martins SP; Peixoto F; Smaletz O; Schutz F; Herchenhorn D; Santos T; Mavignier Carcano F; Queiroz Muniz D; Nunes Filho PRS; Zaffaroni F; Barrios C; Fay A
BMC Cancer; 2019 May; 19(1):487. PubMed ID: 31122212
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Pharmacother; 2019 Feb; 20(2):163-172. PubMed ID: 30462924
[TBL] [Abstract][Full Text] [Related]
15. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor antagonists in castration-resistant prostate cancer.
Rathkopf D; Scher HI
Cancer J; 2013; 19(1):43-9. PubMed ID: 23337756
[TBL] [Abstract][Full Text] [Related]
17. Apalutamide for the treatment of prostate cancer.
Rathkopf DE; Scher HI
Expert Rev Anticancer Ther; 2018 Sep; 18(9):823-836. PubMed ID: 30101644
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide: First Global Approval.
Al-Salama ZT
Drugs; 2018 Apr; 78(6):699-705. PubMed ID: 29626324
[TBL] [Abstract][Full Text] [Related]
19. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
Dror CM; Chi KN
Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
[TBL] [Abstract][Full Text] [Related]
20. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Al-Salama ZT
Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
